Genkyotex : Résultats intermédiaires dans la PBC confirmés pour début novembre
>9.3 M€ de cash à fin juin 2018 - Genkyotex a communiqué hier soir ses résultats du S1 2018. La biotech ne réalise pas encore de CA, la perte opérationnelle s’élève à 4.8 M€ (vs -4.9 M€ en 2017 après retraitement de 15.3 M€ de charge non récurrente liée au rapprochement stratégique opéré début 2017). La trésorerie au 30 juin s’élevait à 9.3 M€ (vs 14.6 M€ fin 2017), ce chiffre n’inclut pas le paiement reçu pour l’extension de l’accord de licence avec SIIL (0.75 M€), l...Genkyotex is engaged in the identification and development of selective NADPH Oxidase ("NOX") inhibitors to treat specific diseases, the therapeutic benefit of which has not yet been demonstrated. Co. is developing a new therapeutic approach based on the selective inhibition of NOX enzymes which are identified as potentially key factors in the development of certain complex illnesses that are difficult to treat, such as hepatic, pulmonary and renal fibrosis, certain forms of cancer, neurodegenerative diseases or even hearing problems. The capacity of NOXs to simultaneously regulate protein networks makes them a therapeutic target.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.